Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAP-1502 spray for adult seborrheic dermatitis
ChiCTR2400085054Phase 3Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of TAP-1502 in seborrheic dermatitis (SD) (5 arms), sponsored by Peking University People's Hospital. Primary endpoint: IGA response rate at Day 56. Planned start May 2024; status: not yet recruiting.
02
Drugs
TAP-1502
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on ChiCTR2400085054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085054.